Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery Versus Biologics for Symptomatic Stricturing Crohn's Disease
NCT05421455Recruiting
- Sponsor
- Weiming Biopharma
- Start
- Jun 2022
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Randomised, open-label trial in Crohn's disease (2 arms), sponsored by Weiming Biopharma. Primary endpoint: Clinical Remission Rate at 1 year. Started Jun 2022; status: recruiting.
02
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05421455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421455.